Morepen Laboratories Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0pusyx8755drdlt736a0ym45.pdf

Key Takeaways


Medical Devices: The "Printer Cartridge" Engine

Suri: "If I grow 20 lakh meter, 25 lakh, 30 lakhs, but the number of Strips will keep on increasing because for every meter we have installed, so that delta is increasing every time so the margins are increasing."

API: Volume Growth Under Price Pressure

Suri: "Even to get 14% growth in the annual revenue, we had to produce 39% more quantity to keep our target. So, we were on the toes for whole of the year."

Formulation & OTC: The Turnaround Bet

Suri: "Formulation and OTC, we are, I would say not on the head runway and we are just trying to see okay, how can we make this business profitable and maybe at some stage divest it or get a partner or get into a separate Company."

Capacity, Reach & the Export Opportunity

Suri: "Now, we are coming out of the cocoon, you don't have the peak of Rs. 500 crores, we have to plan for Rs. 5,000 crores. So, for Rs. 5,000 crores we had to earn capacities."

Financial Health & Segment Math


Strategic Initiatives & New Bets

Suri: "We see that this unique opportunity which we are eyeing upon... a much bigger opportunity than tracking our neck on formulation business or on any other generic business."

Guidance & Commitments

CommitmentSpecificsTimeline
Formulation breakevenSegment to stop losing money now that high-speed capacity is installedFY25
Formulation revenue scale-upTopline to reach 2.5x to 3x current levels (~Rs. 100 crores to ~Rs. 300 crores)Coming two years
API peak revenue capacityExisting gross block can support ~Rs. 1,150 crores in API revenueWith small additions to gross block
Medical devices subsidiary moveBusiness to begin moving into the separate legal entityWithin this financial year
Retail footprint expansionGrow from 1,25,000 to 300,000 retailersNext 5 years
New API product revenue shareIncrease from 10% to 30% of API revenueNext 5 years
Meter sales volume rampPlanned trajectory: 30 lakh meters this year, then 36 lakhs, 40 lakhs, and expandingAnnual progression

Key Metrics

MetricQ4 FY24
Revenue₹1,704 cr, +20% YoY (annual); Q4 revenue +16.5% YoY
EBITDA₹52 cr, +182% YoY from ₹18 cr; margin 12.31% vs 5% YoY
Profit before tax₹42 cr, +279% YoY from ₹11 cr; margin 9.88% vs 3% YoY
Profit after tax₹97 cr (annual), +150% YoY; Q4 PAT margin 6.73% vs 2.25% YoY
Earnings per share₹1.88 per ₹2 share, +144% YoY (annual)
Return on equity11%, vs 5% last year (annual)
Return on capital employed15%, vs 7.31% last year (annual)
Medical Devices revenue₹443 cr (annual), +35% YoY; Q4 +28% YoY and +28% QoQ
API revenue₹271 cr, +25% YoY from ₹217 cr; annual ₹940 cr, +14% YoY
API volume sold432 metric tons (annual), +39% YoY from 311 metric tons
Glucometer business revenue₹342 cr (annual), out of ₹447 cr Medical Devices total
Glucose Strips sold36 cr Strips (annual); average 35 cr, expecting up to 40 cr
Glucose meters installed base1.16 cr cumulative meters in market
BP Monitor meters sold10.51 lakh meters (annual), +29% YoY from 8 lakh meters
Formulation & OTC revenue growth+10% YoY (annual); Q4 +2% YoY
Formulation EBITDA loss₹4 cr loss in Q4; ₹19.5 cr loss annual
API EBITDA margin18%, improved from ~16% last year
Medical Devices EBITDA margin12%, improved from 8% last year
Debt equity ratio0.03, negligible debt
Asset turnover ratio~9x